Core Insights - Yidu Technology (2158.HK) has been recognized as one of the "Best IR Hong Kong Companies" by New Fortune, marking the second time the company has received this award and highlighting its governance, investor relations management, and long-term value [2][4] Group 1: Award Recognition - The award reflects the deep recognition from the capital market and investment community regarding the company's governance capabilities and investor relations management [2][4] - Yidu Technology is the only company in the AI medical sector to be included in this prestigious list [2] Group 2: Evaluation Process - The selection process involved an objective quantitative assessment, narrowing down from 326 candidates to the top 60% for final evaluation [4] - A diverse jury composed of regulatory representatives, professional analysts, institutional investors, financial media, and experts conducted the final voting [4] Group 3: Investor Relations Management - Since its listing in Hong Kong in 2021, Yidu Technology has prioritized investor relations through various activities such as performance briefings, technology open days, and investor days [5] - The company has maintained strong communication channels, including investor hotlines and emails, to provide timely updates on business progress [5] Group 4: Technological Innovation - Yidu Technology is a leading player in China's AI medical field, driven by its core algorithm engine, "YiduCore," which has processed over 5.5 billion medical records [5][6] - The company has established an ecosystem covering 2,800 hospitals, leading the market in research business share and real-world research [5] Group 5: Future Outlook - The recent award underscores the strategic foresight of Yidu Technology's dual-driven approach of technological and capital value [6] - As AI medical technology transitions from validation to large-scale commercialization, the company aims to continue driving intelligent upgrades in the medical field, creating long-term value for shareholders and society [6]

来源：环球网 2025年4月24日，中国科大校友企业心之声联合北京大学健康医疗大数据国家研究院正式发布全球首个 生命体征大模型——DeepLife，突破性地实现了对家用医疗器械、可穿戴设备全场景生命体征数据的直 接解析，为用户提供呼吸、循环、神经、消化、泌尿、内分泌、生殖、运动、免疫等9大系统的实时风 险评估与个性化健康管理服务，标志着AI医疗从辅助诊疗迈向主动健康守护的新时代，真正实现"24小 时在线的AI家庭医生" 。 突破性技术：能直接"理解"生命体征数据的大模型 DeepLife的核心优势在于其对生命体征数据的直接理解和分析能力。通过与多种家用医疗器械和可穿戴 设备的无缝对接，DeepLife能够"理解"包括心电、脑电、PPG、呼吸、血氧、血压、血糖等在内的多种 健康数据，并基于个性化数据进行健康状态分析和趋势预测。 并且，DeepLife突破了传统医疗体系的局限，不仅能够对单一健康指标进行解析，还能对人体"九大系 统"进行整体健康风险分析。目前，DeepLife已覆盖ICD-10国际疾病分类中的1859种疾病风险预测，后 续版本将逐步扩展至更多疾病种类。通过"AUROC受试者工作特征曲线下面积"评测 ...

Group 1: Hong Kong Stock Market Performance - The Hang Seng Index rose by 1.36%, gaining 297 points to close at 22,206 points, while the Hang Seng Tech Index increased by 1.87% [1] - The early trading volume in the Hong Kong stock market reached HKD 116.4 billion [1] Group 2: Real Estate Sector - Foreign institutions are optimistic about the recovery of the Chinese real estate sector, with Citigroup strategists urging investors to increase their holdings in Chinese real estate stocks due to expected improvements in profitability from policy support and better management practices [1] - Kwan Hung Holdings surged over 43%, while other notable gains included Rongxin China up 17%, Greentown China up 5%, CIFI Holdings up 7.88%, Sunac China up 4.22%, and Longfor Group up 6.74% [1] Group 3: AI Medical Sector - AI medical concept stocks saw an uptick as seven departments jointly promoted AI empowerment across the pharmaceutical industry, with institutions optimistic about the accelerated trend in the AI medical industry [1] - Notable stock performances included iFlytek Medical Technology up 7.2%, Yidu Tech up 5.35%, Crystal Tech Holdings up 4.69%, and MicroPort Scientific up 4.07% [1] Group 4: Other Notable Stocks - Horizon Robotics rose over 7% following a strategic partnership with Bosch to develop an upgraded version of Bosch's advanced driver assistance system [2] - KPB Medical surged over 14%, with a cumulative increase of over 95% this week after its core product was approved for sale in China [3] - Xintai Medical increased by 3.88%, although the company indicated uncertainty regarding its sales growth targets [4] - Minmetals Resources rose over 5%, reporting a 76% year-on-year increase in copper production for the first quarter, with potential adjustments to production guidance [5] - Beike-W increased by 4.88%, as the real estate fundamentals became clearer, with institutions suggesting its stock price is entering a value range [6] - Global New Materials International saw a sharp rise of over 20% before settling at a 4% increase after acquiring Merck's global performance solutions business [7]

Group 1 - The core viewpoint of the article highlights the positive market response to the announcement of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by the Ministry of Industry and Information Technology and six other departments, which emphasizes the integration of artificial intelligence in the pharmaceutical sector [1] - Companies such as Yidu Tech (02158.HK), Jingtai Holdings (02228.HK), Yimai Tong (02192.HK), and MicroPort Scientific Corporation-B (02252.HK) experienced significant stock price increases, with Yidu Tech rising by 6.27%, Jingtai Holdings by 4.08%, Yimai Tong by 2.13%, and MicroPort by 1.86% following the news [1] - The plan encourages the establishment of innovative platforms for pharmaceutical large models, promoting collaborative research and development of technology products and regulatory science within the industry [1] Group 2 - The initiative aims to strengthen the construction of standards, norms, technological ethics, application safety, and risk management in the pharmaceutical industry [1] - The focus on artificial intelligence applications is expected to enhance the overall efficiency and innovation capacity of the pharmaceutical sector [1]

以下文章来源于乌鸦智能说 ，作者智能乌鸦 乌鸦智能说 . 人人都能读懂的AI商业 今年 2 月，硅谷 AI 营养平台 Fay 完成了由高盛领投的 5000 万美元融资，公司估值冲到 5 亿美元。 据悉，Fay 已经累计融到了 7500 万美元的投资。作为一个连接营养师和患者的在线平台， Fay 凭借仅有不到 3000 个的营养师，实现了 5000 万美金 的年收入。 Fay 极其突出的商业化表现引发了外界对于「AI+医疗」领域的商业化模式思考。 总结来看，Fay 成为 AI 医疗领域「范本」的主要核心优势在于： 通过与保险公司深度绑定，将自身平台嵌入健康保险系统中，Fay 建立了牢固的护城河。 Founder Park 正在搭建开发者社群，邀请积极尝试、测试新模型、新技术的开发者、创业者们加入，请扫码详细填写你的产品/项目信息，通过审核 后工作人员会拉你入群～ 进群之后，你有机会得到： Sammy Faycurry（⾸席执⾏官）和 Mark Stefanski（⾸席技术官） 找准时机，踩中风口： 2022 年以来，美国「减肥潮」兴起，市场对专业营养服务的需求暴增，但营养师的供给严重不足。Fay 基于 AI 技 ...

左医科技是业界领先的知识图谱和医疗大模型协同驱动的医疗科技公司。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 2025年将是 AI 应用的爆发之年，这几乎已成为一种共识。 内唯一对标微软Nuance DAX的听译机器人，直接从医患沟通语音中生成病历 ； 2023年5月 ， 左 医科技率先发布医疗垂类大模型，并应用落地与四川省人民医院、北京天坛医院等百强医院，并助力 全国排名前三的儿科医院重庆医科大学附属儿童医院打造行业首个儿科医疗基座大模型。 此外， 左 医科技基于 multi-agent技术打造的AI医生，同宁夏中卫市、银川市、北京西城区卫健委签约，将 AI医生升级为AI家医作为现有家庭医生服务的有效补充。 截至目前， 左医科技打造的 "左手医生"品牌 已成为 国内领先的全科智能医生，提供 AI家庭医生、 智能导诊、预问诊、诊室听译机器人、智能在线问诊等解决方案，通过与不同应用场景的结合，提供 优质的医疗服务，赋能医疗健康行业，现已覆盖200余家三甲医院，其中超过40家为Top100医院。 在发布新一代 AI医疗 产品之际， 左医科技创始人 兼 CEO张超 向「 ...

Core Insights - The emergence of the domestic AI model DeepSeek has sparked significant interest in the AI+ healthcare sector in China, with predictions of substantial industry growth by 2030 [1] - The AI healthcare market is expected to grow at an annual rate of 43% from 2024 to 2032, potentially reaching a market size of $491 billion [1] - The company Zhiyun Health is positioned as a leading provider of chronic disease management and healthcare solutions in Hong Kong, focusing on strategic upgrades and business optimization [1][2] Company Performance - Zhiyun Health reported total revenue of approximately 3.49 billion RMB, with a slight increase in gross margin to 24.7%, despite an expanded net loss due to the disposal of non-core businesses [2][4] - The company's core business, the hospital solution segment, has shown robust growth through its unique "Touch, Deploy, Commercialize" (AIM) model, with over 2,700 hospitals adopting its SaaS products [3][4] Strategic Initiatives - The "P2M" strategy has been implemented to enhance operational efficiency and optimize business structure, resulting in a significant increase in revenue from P2M solutions, which reached 320 million RMB, nearly doubling year-on-year [4][5] - The company has signed contracts with 45 pharmaceutical companies, with a total of 55 SKUs, indicating strong collaboration in the pharmaceutical sector [4] Market Environment - The healthcare industry is undergoing significant changes due to centralized procurement reforms, with price reductions of 20% to 30% expected for many common drugs, which may pressure traditional business models [2] - The AI+ healthcare market is projected to exceed 100 billion RMB by 2026, with a compound annual growth rate of over 30%, presenting a substantial growth opportunity for companies like Zhiyun Health [7] Technological Advancements - Zhiyun Health has developed two vertical models, ClouD GPT and ClouD DTx, which excel in patient interaction and medical research, contributing to a comprehensive digital chronic disease management service [7][8] - The integration of the DeepSeek-R1 model into the company's AI system aims to enhance chronic disease management efficiency by leveraging over 1 billion electronic medical records [8] Future Outlook - With ongoing policy support and technological innovation, the AI+ healthcare market in China is expected to thrive, providing a favorable environment for Zhiyun Health's growth [6][7] - The company's strategic focus on optimizing its business structure and enhancing its AI capabilities positions it well for sustained growth and increased market share in the evolving healthcare landscape [9]

长按即可参与 3、AI医疗产业端落地成熟度，影像→体外诊断→医疗机器人→制药→慢病管理→医疗信息化。 4、AI+诊断领域： 1）体外诊断公司：主业有业绩压力，但需给予AI属性估值溢价。关注与大厂绑定深、落地成熟的 公司。 2）影像公司：如联影，在设备市场铺设、市占率、数据授权上有优势。 3）业绩变好公司：对主业业绩有包容度，关注可能迎来拐点的公司。 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 巴菲特读书会 来源：雪球 1、AI医疗产业整体前景大，能够赋能医疗产业端公司的传统业务，提升其盈利能力，并在客户绑 定、新客户开拓上提供帮助。 2、在患者端，AI医疗可以提高了医疗资源的可及性，使得偏远地区的人能够触达到高等级的医疗 资源（医疗资源平权）；还可以减少漏诊和误诊，提高诊断的准确性（诊断准确性）；以及AI制 药如果成功，患者将受益（制药）。 4）细分领域数据公司：如华大智造，除数据、AI逻辑外，还受Illumina被禁入中国市场影响。 5、AI+医院/医生：AI能提高医生和医院的诊断治疗能力；对医院和医生的运营效率有帮助。 6、AI+慢病管理：看好AI慢病管理 ...

Group 1: IDC Industry Insights - The global IDC sector has experienced significant volatility, with U.S. companies affected by macroeconomic factors and tariff policies, while domestic IDC companies faced major pullbacks due to concerns over annual revenue and Capex outlooks [1] - Leading companies in the IDC sector maintain cautious capital expenditure plans while leveraging network effects to enhance customer stickiness and revenue optimization [1] - The performance realization cycle for domestic IDC companies is lengthy, with 25H2 expected to be a critical observation window for performance realization [1] Group 2: AI in Healthcare - AI healthcare applications are primarily focused on doctor copilot systems, with potential for department-level and hospital-wide intelligent systems [2] - The long-term market potential for AI applications in healthcare is estimated to be nearly 100 billion yuan, with a focus on companies that can access hospital data to enhance AI model capabilities [2] - The competitive landscape is expected to evolve, with a shift towards hospital information technology vendors as AI capabilities become more widespread [2] Group 3: Asset Allocation and ETFs - The launch of the State Street-Bridgewater All Weather ETF reflects a trend towards multi-asset ETFs in the U.S., which aim to diversify risk across various economic environments [3] - The product has shown resilience during market adjustments, highlighting the benefits of a diversified investment strategy [3] - Active management of multi-asset ETFs is emerging as a key innovation direction in overseas markets [3] Group 4: Fiscal Policy and Economic Outlook - The 2025 fiscal budget reflects low revenue growth targets due to domestic and international pressures, while maintaining high expenditure levels for counter-cyclical adjustments [5] - The estimated broad fiscal deficit for this year is approximately 11.4 trillion yuan, corresponding to a broad deficit rate of about 8.0%, marking historical highs [5] - Early fiscal spending has outpaced revenue, indicating a proactive approach to support livelihoods and technological innovation, which may aid in economic recovery [5] Group 5: Exoskeleton Robots - Exoskeleton robots are gaining traction across various sectors, including industrial, logistics, and healthcare, driven by advancements in AI and industrial control technologies [7] - The aging population and increasing demand for healthcare solutions present significant market opportunities for exoskeleton applications [7] - Companies focusing on core components and related equipment in the exoskeleton market are recommended for investment [7] Group 6: Energy Storage and Inverters - The inverter sector is experiencing a rebound, with market sentiment improving as fundamental turning points and valuation corrections are anticipated [9] - Long-term prospects for the energy storage industry are positive, with expectations for technology premiums to drive market expansion [9] - The inverter segment is viewed as a high-probability investment opportunity during the upcoming performance vacuum period in April [9] Group 7: Nuclear Fusion Equipment - Recent advancements in nuclear fusion are expected to enhance the commercial pace of related technologies, benefiting domestic equipment manufacturers [10] - Key suppliers in the nuclear power sector are well-positioned to capitalize on the growth of nuclear fusion technology [10] - The outlook for equipment manufacturers in the nuclear fusion space is optimistic, given the anticipated policy support and technological breakthroughs [10]

百川精简医疗团队，AI医疗的金矿不好挖 文｜光锥智能 魏琳华 编辑｜王一粟 3月4日，继裁撤金融、教育团队，全力主攻最重要的医疗项目后，在不到半个月的时间内，百川再度调 整团队。 3月18日，有百川员工告诉光锥智能，目前百川智能医疗团队正在裁员，预计会将团队人数规模精简在 一定范围内。 对此，百川智能回复光锥智能，百川智能会集中资源、聚焦核心业务，加速实现"造医生、改路径、促 医学"的愿景。此前，在与北京儿童医院的深度合作中，百川智能共同研发的AI儿科医生已在疑难病例 的顶级专家会诊中正式"上岗"，作为全球医疗领域AI医生的首次应用，获得了专家组的高度评价与认 可。未来，百川将以更高效的团队和更丰富的资源，持续推动优质医疗服务的普及与普惠。 就在当日，百川智能的两位联合创始人也被曝出走。据蓝鲸新闻消息，联合创始人焦可已经离职，另外 一位联合创始人陈炜鹏也正在走离职手续。 在基模之战白热化的当下，商业化成了"六小虎"的关键问题。缩减AI医疗团队的百川，正在调整寻找更 适合当下的路。 商业化难，AI医疗的金矿不好挖 2024年，百川开始明确地打出了"AI+医疗"的旗帜。 谈及为何在一年后才作出转变，王小川给出的回 ...